FTD-TPI Plus Bevacizumab Increases Survival in Refractory Advanced CRC

THURSDAY, May 4, 2023 -- Treatment with trifluridine-tipiracil (FTD-TPI) plus bevacizumab yields longer overall survival than FTD-TPI alone among patients with refractory metastatic colorectal cancer, according to a study published in the May 4...